INRLF (INRLF) Stock Price & Analysis
INRLF (INRLF) rose 0.00% to USD 2.62 as of July 26, 2026 at 08:56 UTC, according to Nexqual real-time market data.
INRLF last closed at USD 2.62; the session ranged USD 2.77–2.77 on volume of 89 shares. Market capitalization is $535.11M, with a 52-week range of USD 2.46–6.28 (PNK). Source: Nexqual, July 26, 2026 at 08:56 UTC.
Key Statistics (as of July 26, 2026 at 08:56 UTC)
| Price | USD 2.62 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 2.62 |
| Open | USD 2.77 |
| Day Range | USD 2.77 – 2.77 |
| 52-Week Range | USD 2.46 – 6.28 |
| Volume | 89 shares |
| Market Cap | $535.11M |
| Exchange | PNK |
Technical Analysis (INRLF)
Nexqual's technical model rates INRLF "NEUTRAL" based on 3 bullish and 3 bearish signals across 125 daily candles, as of July 26, 2026 at 08:56 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 33.33 (neutral) |
| vs SMA50 | Above (USD 2.61) |
| MACD | -0.01 (negative) |
Analyst Ratings (INRLF)
Wall Street analysts rate INRLF "None", per Nexqual as of July 26, 2026 at 08:56 UTC.
| Consensus Rating | None |
|---|
Earnings (INRLF)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $37.72M |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Financials & Fundamentals (INRLF)
| Total Revenue | $156.33M |
|---|---|
| Revenue Growth (YoY) | -37.20% |
| Gross Margin | -25.27% |
| Operating Margin | -76.67% |
| Profit Margin | -88.30% |
| ROE | -109.57% |
| Debt / Equity | 273.15 |
| Current Ratio | 2.14 |
| Total Cash | $105.27M |
| Total Debt | $209.50M |
| Free Cash Flow | $-31.01M |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Financial Health Score (INRLF)
Nexqual rates INRLF's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 08:56 UTC.
| Growth | Mixed — Revenue +3.0% YoY (annual), slow |
|---|---|
| Profitability | Critical — Gross margin -25%, operating -77% |
| Balance Sheet | Weak — $105M cash vs $210M debt |
| Cash Flow | Weak — FCF negative: -$31M, burning cash |
| Efficiency | Critical — ROE -110%, ROA -14.5% |
Ownership (INRLF)
| Insider Ownership | +10.72% |
|---|---|
| Institutional Ownership | +24.30% |
| Shares Outstanding | 204.24M |
| Float | 147.76M |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Leadership (INRLF)
INRLF is led by Thomas Lingelbach (age 62), President, CEO & Director, per Nexqual as of July 26, 2026 at 08:56 UTC.
| President, CEO & Director | Thomas Lingelbach (age 62) |
|---|---|
| Chief Financial Officer | Peter Buhler (age 54) |
| Chief Operating Officer | Vincent Dequenne (age 58) |
| Chief Scientific Officer | Hanneke Schuitemaker (age 60) |
| Vice President of Investor Relations | Joshua Drumm |
Major Backers & Investors (INRLF)
Notable institutional backers of INRLF include General American Investors Company, Inc., according to Nexqual as of July 26, 2026 at 08:56 UTC.
Active Investors
| Investor | Stake |
|---|---|
| General American Investors Company, Inc. | 0.83% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.28% |
| State Street | 0.18% |
Source: Nexqual, July 26, 2026 at 08:56 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VALN | Valneva SE | USD 4.78 | ▼ 2.45% |
| OXBDF | Oxford Biomedica PLC | USD 8 | ▲ 0.88% |
| CASBF | CANSINO BIOLOGICS INC | USD 3.15 | ▲ 0% |
| IDRSF | IDORSIA LTD | USD 7.6 | ▲ 0% |
| PTCHF | PureTech Health PLC | USD 1.6 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 08:56 UTC. This page is informational and not investment advice.